Source comparison
PT-141 vs Bremelanotide: Research Applications Comparison
Molecular Identity Cyclic heptapeptide melanocortin agonist Identical cyclic heptapeptide Chemically indistinguishable. Same amino acid sequence Regulatory Status Non-FDA-approved; 503A/503B compounded FDA-approved (2019) for HSDD in women Bremelanotide has co
This comparison does not assign a generated winner or score.
- Molecular Identity
- Cyclic heptapeptide melanocortin agonist
- Identical cyclic heptapeptide
- Chemically indistinguishable. Same amino acid sequence
- Regulatory Status
- Non-FDA-approved; 503A/503B compounded
- FDA-approved (2019) for HSDD in women
- Bremelanotide has completed Phase III trials; PT-141 is research-only
- Typical Purity
- 97–98% via HPLC (supplier CoA)
- ≥99% (FDA batch verification)
- 1–2% purity gap is pharmacologically negligible
- Dosing Flexibility
- Fully adjustable (0.5–5.0mg range)
- Fixed 1.75mg per autoinjector
- PT-141 allows dose titration; Vyleesi does not
- Cost per Dose (1.75mg)
- $8–$15 (from 10mg vial)
- $950–$1,100 (single autoinjector)
- 60–80× price difference for the same active peptide
- Storage Requirements
- −20°C powder; 2–8°C reconstituted
- 2–8°C pre-filled injector
- Both degrade above 8°C. No storage advantage